News >

Pegilodecakin Falls Short in Phase III Pancreatic Cancer Trial

Jason M. Broderick @jasoncology
Published: Wednesday, Oct 16, 2019

Maura Dickler, MD, vice president, late phase development, Lilly Oncology

Maura Dickler, MD

Combining the pegylated IL-10 pegilodecakin with FOLFOX (folinic acid, 5-FU, oxaliplatin) chemotherapy did not improve overall survival (OS) as a second-line therapy for patients with metastatic pancreatic cancer, according to topline results from the phase III SEQUOIA trial.1

 

References

  1. Lilly announces phase 3 study in patients with metastatic pancreatic cancer did not meet primary endpoint of overall survival. Posted October 16, 2019. Accessed October 16, 2019. https://prn.to/2VMNc2p.
  2. Hecht JR, Naing A, Falchook GS, et al. Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX). Ann Oncol. 2018;29(8 suppl, abstr 1143P). doi: 10.1093/annonc/mdy288.016.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x